For well over three and a half years, the story had been the DoJ wasn't making many criminal waves -- on pharma pricing. As of this morning, that all changes -- and may change things, for Martin. He may have a new criminal indictment. . . coming, even as he is still incarcerated at FCI Allenwood, Low.
I had speculated a couple of weeks ago that if the FTC was looking at a potentially criminal parallel antitrust investigation, it would transfer the same over to the DoJ for charging decisions -- and indictments.
I speculated about that, because it became clear that the FTC in the Daraprim® civil case was receiving (via FOIA) a treasure trove of evidence from Martin's own mouth and keyboard -- from FCI Ft. Dix. -- likely against Vyera / Phoenix as well as against Martin and Mr. Mulleady personally.
Here is the overnight Bloomberg breaking news story -- as to Teva -- that animates all of this and a bit of it:
. . .The U.S. business of Teva Pharmaceutical Industries Ltd. was indicted Tuesday on charges the generic drugmaker fixed prices on cholesterol medications, and other drugs....
Charges against Teva, the world’s largest generic-drug maker by market value, mark the most significant case to come out of the Justice Department’s years-long investigation into allegations that companies conspired with one another to prop up the prices of certain widely used medications. Nine of every 10 prescription drugs dispensed in the U.S. are generics. [Ed. Note: pyrimethamine, the active ingredient in Daraprim -- is now also a generic, via Cerovene.]
Five other companies have settled charges and agreed to pay a total of $426 million in criminal penalties. . . .
Now you know -- but Martin may yet do well over a decade inside, when the dust all settles -- just as I guessed in March of 2018.
Onward. . . after a very rough night in Kenosha -- three shot; two dead. This is not the answer, people. Leave the guns at home.
नमस्ते
No comments:
Post a Comment